患病类调节神经退行的影响:对A/T/N的影响
Donald R Royall1,2,3,4, Raymond F Palmer3,
1Department of Psychiatry, the University of Texas Health Science Center, San Antonio, TX, USA.
Journal of Alzheimer's disease : JAD
|December 22, 2025
概括
一个新的算法可以识别那些能够抵抗神经退行症的个体.
科学领域:
- 神经科学是一个神经科学.
- 生物标志物研究 生物标志物研究
- 阿尔茨海默病 阿尔茨海默病
背景情况:
- 阿尔茨海默病 (AD) 的生物标志物 (粉样性病,性病,神经退行) 是关键指标.
- 个体对这些生物标志物的抵抗力存在,需要方法来区分受影响的和不受影响的个体.
- 之前的工作建立了一个心理测量算法,用于与炎症,阿迪波金和粉样蛋白病变相关的弹性.
研究的目的:
- 在阿尔茨海默病 (AD) 弹性背景下分析神经退行.
- 开发和验证一种基于神经退行性疾病的个人分类方法.
- 评估神经退行性疾病对痴呆症严重程度和转化为临床AD的影响.
主要方法:
- 利用了阿尔茨海默病神经成像计划 (ADNI) 1737名参与者的数据.
- 从三个生物标志物开发了神经退行"N因子",并使用"dTEL"评估了痴呆症的严重程度.
- 使用基于dTEL余量和通过生存分析对临床转换的测试类效应的"身份线 (LOI) "方法将参与者分为患病类别.
主要成果:
- 近一半 (49.4%) 的ADNI参与者被归类为患有神经退行症.
- "受影响"组表现出更严重的痴呆症严重程度,较差的N因子得分,以及更高的中枢神经系统神经退行.
- 受影响的个体在48个月内转化为临床AD的可能性明显更高.
结论:
- 开发的心理算法有效地区分了患有神经退行症的个体.
- 这种方法提高了生物标志物效应的预测,并支持AD的精准医学策略.
- 识别神经退行性弹性对于理解AD进展和定制干预措施至关重要.
相关概念视频
Disorders of the Nervous Tissue
2.5K
Nervous tissue is a vital component of the human body's communication system, enabling us to perceive and respond to stimuli. However, like all other tissues, it is vulnerable to disorders and diseases that can significantly impact our neurological functioning.
Homeostatic Imbalances:
Alzheimer's disease manifests as a gradual decline in memory and cognitive abilities, attributed to the buildup of amyloid plaques and neurofibrillary tangles in the brain.
Parkinson's disease arises from the...
Homeostatic Imbalances:
Alzheimer's disease manifests as a gradual decline in memory and cognitive abilities, attributed to the buildup of amyloid plaques and neurofibrillary tangles in the brain.
Parkinson's disease arises from the...
2.5K
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Neural Regulation
43.0K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
43.0K
Alzheimer's Disease: Treatment
752
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
752
Parkinson's Disease: Overview
1.7K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.7K
Drugs Affecting Neurotransmitter Synthesis
2.1K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.1K


